https://www.selleckchem.com/pr....oducts/verubecestat.
8; 95% CI [1.0-92.9]). Overall survival (OS) was similar in both age groups (log rank=0,95). In our study, octogenarians and patients 80years had equivalent survival, across the different thoracic cancer treatments and tumor stages. Measure of muscle strength in CGA could be very useful in a clinical setting to help improve the management of older old patients treated for lung or thoracic cancer. In our study, octogenarians and patients less then 80 years had equivalent survival, across the different thoracic cancer treatments
Like
Comment
Share
